STOCK TITAN

Bausch Health (BHC) director awarded $250K in RSUs

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

LEUNG SANDRA reported acquisition or exercise transactions in this Form 4 filing.

Bausch Health Companies Inc. director Sandra Leung received an equity award as part of her board compensation. She was granted 45,871 restricted share units with a grant date value of $250,000, which will vest on the date immediately before the company’s next Annual Meeting of Shareholders and be settled in common shares. Following this award, she beneficially owns 90,225 common shares directly.

Positive

  • None.

Negative

  • None.
Insider LEUNG SANDRA
Role Director
Type Security Shares Price Value
Grant/Award Common Shares, No Par Value 45,871 $0.00 --
Holdings After Transaction: Common Shares, No Par Value — 90,225 shares (Direct)
Footnotes (1)
  1. [object Object]
RSUs granted 45,871 units Award to non-employee director on third business day after election
Grant date value <money>$250,000</money> Value of RSU award to non-employee directors
Shares owned after award 90,225 shares Common shares beneficially owned following the RSU grant
Transaction code A (award acquisition) Grant, award, or other acquisition of non-derivative securities
restricted share units ("RSUs") financial
"Represents the award of restricted share units ("RSUs") granted to non-employee directors"
grant date value financial
"The RSUs have a grant date value of $250,000"
vest financial
"The RSUs have a grant date value of $250,000, vest on the date immediately preceding"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
settled in common shares financial
"and are settled in common shares, no par value, of the Issuer"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What did Bausch Health (BHC) director Sandra Leung report on this Form 4?

Sandra Leung reported receiving 45,871 restricted share units as an equity award. These units relate to her role as a non-employee director and are part of her regular board compensation, rather than an open-market stock purchase or sale.

What is the value of the RSU grant reported by BHC director Sandra Leung?

The restricted share units granted to Sandra Leung have a grant date value of $250,000. This amount reflects the compensation awarded to her as a non-employee director following her election at Bausch Health’s Annual Meeting of Shareholders.

When do Sandra Leung’s BHC restricted share units vest?

Sandra Leung’s restricted share units vest on the date immediately preceding Bausch Health’s next Annual Meeting of Shareholders. Vesting means the units become earned at that time, after which they are eligible to be settled in common shares of the company.

How will Sandra Leung’s Bausch Health RSUs be settled?

The restricted share units granted to Sandra Leung will be settled in Bausch Health common shares. Once the units vest immediately before the next Annual Meeting of Shareholders, she will receive common shares with no par value corresponding to the vested RSUs.

How many Bausch Health shares does Sandra Leung own after this award?

After receiving this restricted share unit award, Sandra Leung beneficially owns 90,225 Bausch Health common shares directly. This figure reflects her reported holdings following the grant, as disclosed in the Form 4 insider transaction filing.

Is Sandra Leung’s BHC Form 4 transaction a market buy or sell?

The Form 4 reflects a grant, not a market buy or sell. The transaction is coded as an award of restricted share units to a non-employee director, with no purchase price and no open-market trading activity reported in this filing.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
LEUNG SANDRA

(Last)(First)(Middle)
400 SOMERSET CORPORATE BLVD.

(Street)
BRIDGEWATER NEW JERSEY 08807

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Bausch Health Companies Inc. [ BHC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/22/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Shares, No Par Value05/22/2026A45,871(1)A$090,225D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents the award of restricted share units ("RSUs") granted to non-employee directors of the Issuer on the third business day following their election at the Issuer's Annual Meeting of Shareholders. The RSUs have a grant date value of $250,000, vest on the date immediately preceding the Issuer's next Annual Meeting of Shareholders, and are settled in common shares, no par value, of the Issuer.
/s/ Brianna M. Dorsi, attorney-in-fact05/26/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)